Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
VEGFR TKI
Sunitinib
Sutent · Suni
A VEGFR tyrosine kinase inhibitor whose anti-angiogenic action injures the glomerular endothelium and podocyte, producing near-ubiquitous hypertension, proteinuria, and, in severe cases, a renal-limited thrombotic microangiopathy.
ModerateVEGFR TKI · approved 2006
Metastatic/advanced renal cell carcinoma (first-line)Imatinib-resistant or intolerant gastrointestinal stromal tumor (GIST)Advanced pancreatic neuroendocrine tumorsAdjuvant therapy of high-risk RCC after nephrectomy
Signature kidney injury
Hypertension
Representative incidence21.6%
In a systematic review/meta-analysis of 4,999 patients across 13 trials, all-grade hypertension occurred in ~21.6% and high-grade hypertension in ~6.8% of sunitinib-treated patients, with a significantly increased risk of renal dysfunction versus controls (RR ~1.36); risk varied by tumor type and dosing schedule. Proteinuria is common but less consistently quantified, and severe glomerular lesions (thrombotic microangiopathy, nephrotic-range proteinuria) are reported mainly at the case-series level. Reported figures are class-consistent with other VEGF-pathway inhibitors.
Source: Zhu, Acta Oncol 2009
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so characteristic it has been studied as a pharmacodynamic marker of drug exposure.
Mechanism of kidney injury
VEGF produced by podocytes maintains the health of the adjacent glomerular endothelium and its fenestrae. Sunitinib's VEGFR blockade removes this paracrine support, causing endothelial dysfunction, loss of fenestration, reduced nitric oxide and prostacyclin, and a rise in endothelin-1 — yielding systemic hypertension and a glomerular endotheliosis/thrombotic microangiopathy phenotype (subendothelial widening, mesangiolysis, capillary microthrombi, GBM double contours, foot-process effacement). Eremina and colleagues showed that podocyte-specific VEGF deletion in mice reproduces a thrombotic glomerular injury, providing direct evidence that local glomerular VEGF reduction is sufficient to trigger the lesion. Hypertension and afferent vasoconstriction can also produce a reversible, largely hemodynamic ('pre-renal'-type) decline in GFR.
Clinical presentation
Most commonly new or worsening hypertension within the first cycles, often accompanied by proteinuria that ranges from low-grade to nephrotic. More severe presentations include acute kidney injury with hypertension, nephrotic syndrome, microangiopathic hemolytic anemia/thrombocytopenia, and hematuria when overt thrombotic microangiopathy develops. Reversible serum creatinine rises occur and may reflect hemodynamic change rather than structural injury.
Anticancer mechanism
Oral multitargeted receptor tyrosine kinase inhibitor blocking VEGFR-1/2/3, PDGFR-alpha/beta, KIT, FLT3, CSF1R, and RET. Anti-tumor activity in clear-cell renal cell carcinoma and imatinib-resistant GIST is driven largely by VEGFR/PDGFR blockade, which starves tumors of neovascularization.
Management
Treat hypertension aggressively with standard agents (RAAS blockers are often preferred given concurrent proteinuria), and titrate as needed. For low-grade proteinuria, continue with closer monitoring; for nephrotic-range proteinuria, significant AKI, or suspected/biopsy-proven thrombotic microangiopathy, dose-reduce, interrupt, or discontinue sunitinib — hypertension, proteinuria, and renal function frequently improve or normalize after withdrawal, though some patients have incomplete recovery and rare progression to dialysis (especially if the drug is continued). Renal biopsy helps when the lesion or differential is unclear. Plasma exchange/eculizumab are generally not indicated for this VEGF-blockade ('secondary') TMA, for which drug cessation is the cornerstone.Lesion-level management framework
Risk factors
- Pre-existing hypertension
- Pre-existing chronic kidney disease or proteinuria
- Prior or concurrent VEGF-pathway therapy (e.g., bevacizumab)
- Solitary kidney / prior nephrectomy (common in RCC)
- Higher dose and continuous (vs intermittent) dosing schedules
Prevention
- Baseline and on-treatment blood pressure measurement with prompt antihypertensive therapy
- Baseline and serial urine protein (dipstick/UPCR) and serum creatinine monitoring
- Optimize/treat pre-existing hypertension before and during therapy
- Coordinated onco-nephrology co-management for proteinuria or rising creatinine
Note · Educational reference, not medical advice. Incidence figures derive largely from RCC/GIST trial populations and meta-analysis; severe glomerular/TMA lesions are documented mainly through renal-biopsy case series, so those mechanistic and lesion-specific claims are appropriately hedged.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment is established for mild-to-moderate renal impairment; sunitinib pharmacokinetics are not markedly altered by reduced kidney function, and dosing is guided by tolerability/toxicity rather than eGFR. Standard metastatic RCC dosing is 50 mg daily on a 4-weeks-on/2-weeks-off schedule, with reductions (e.g., to 37.5 mg) for toxicity. Hold or reduce dose for severe hypertension, nephrotic-range proteinuria, or significant AKI.
Dialyzability & ESKD dosing
Sunitinib is highly protein-bound and has a large volume of distribution, so it is not expected to be appreciably removed by hemodialysis; supervised use in dialysis patients has been described, with dosing driven by tolerability rather than dialytic clearance.
Differential diagnosis
Distinguish VEGF-blockade thrombotic microangiopathy from primary/atypical HUS and TTP (ADAMTS13), and from hypertensive nephrosclerosis. A reversible hemodynamic creatinine rise (afferent vasoconstriction from hypertension) should be separated from structural glomerular injury. Proteinuria with bland sediment and hypertension favors the VEGF-pathway lesion; rarely, immune-complex/endocapillary glomerulonephritis and tubulointerstitial injury have been reported, and biopsy may be needed to differentiate.
Monitoring
- Blood pressure at baseline and each visit/cycle (consider home monitoring early on)
- Urine protein (dipstick or urine protein-to-creatinine ratio) at baseline and periodically
- Serum creatinine / eGFR at baseline and during therapy
- CBC for anemia/thrombocytopenia and peripheral smear/LDH/haptoglobin if TMA suspected
Key trials & series
- Phase III trial of 750 treatment-naive metastatic RCC patients showing sunitinib doubled progression-free survival vs interferon-alfa (established it as first-line standard of care)
Clinical pearls
- Hypertension is the signature and earliest renal-vascular signal — it is so common it is sometimes used as a pharmacodynamic marker of VEGF-pathway target engagement.
- The kidney lesion is a glomerular endothelial disease: think podocyte-VEGF withdrawal causing endotheliosis and a renal-limited TMA, not classic platelet-driven HUS/TTP.
- Drug discontinuation — not plasma exchange or eculizumab — is the primary treatment for VEGF-inhibitor-associated TMA; proteinuria and renal function often improve after stopping.
- Many RCC patients have a solitary kidney after nephrectomy, lowering renal reserve and raising the stakes of proteinuria and AKI.
- A modest, reversible creatinine bump can be hemodynamic from hypertension rather than true structural injury — recheck after BP control before escalating.
Beyond the kidney — non-renal toxicities· 4 organ systems
Class-level context for the major non-renal toxicities of vegfr tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Hypertension, arterial/venous thrombosis, bleeding, impaired wound healing
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- LV dysfunction; QT (some TKIs)
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea, perforation/fistula
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Hand-foot skin reaction
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRisk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.Zhu X, Stergiopoulos K, Wu S · Acta Oncol 2009 · PMID 18752081Meta-analysis of 4,999 patients; anchors the headline incidence: all-grade hypertension 21.6%, high-grade 6.8%, and increased risk of renal dysfunction (RR 1.36).LandmarkVEGF inhibition and renal thrombotic microangiopathy.Eremina V, Jefferson JA, Kowalewska J, et al. · N Engl J Med 2008 · PMID 18337603Landmark mechanistic paper: podocyte-specific VEGF deletion in mice reproduces thrombotic glomerular injury, establishing VEGF blockade as the cause of the renal TMA seen with anti-VEGF therapy.PMIDNephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature.Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG · Nephron Clin Pract 2010 · PMID 21051905Case series/review documenting the sunitinib renal toxicity spectrum (hypertension, proteinuria, TMA, AKI/CKD) and its resolution on drug cessation.PMIDAngiogenesis inhibitors: mechanism of action and nephrotoxicity.Clou E, Luque Y · Nephrol Ther 2021 · PMID 34838486Review of VEGF-pathway inhibitor nephrotoxicity; supports hypertension and proteinuria as the commonest, generally reversible effects, with TMA and rarer tubulointerstitial injury as severe forms.PMIDClinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature.Han Q, Li L, Li Z, et al. · Pathol Res Pract 2025 · PMID 39879682Biopsy-confirmed sunitinib-associated TMA: proteinuria as first symptom, mean onset ~23 months, characteristic mesangiolysis/GBM double contours/foot-process effacement, outcomes after withdrawal vs continuation.PMIDSunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report.Zhang X, Wang H, Li J, Zhou F, Zhao M, Su T · BMC Nephrol 2024 · PMID 39215250Case report of severe hypertension, nephrotic syndrome, and AKI with biopsy showing TMA plus glomerulonephritis; rapid improvement after sunitinib discontinuation.PMIDSunitinib for the treatment of metastatic renal cell carcinoma.Oudard S, Beuselinck B, Decoene J, Albers P · Cancer Treat Rev 2011 · PMID 20817406Clinical review providing indications, the 50 mg 4/2 dosing schedule, and the pivotal phase III PFS data versus interferon-alfa.
Guidelines & consensus· 16
KDIGOManagement of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice GuidelineAnn Intern Med 2021 · PMID 34152826Recommends standardized office BP measurement and a target systolic BP <120 mm Hg for most CKD patients, with RAAS inhibitors first-line when albuminuria is present — the BP-management basis for anti-VEGF/TKI-induced hypertension and proteinuria.ESC2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Eur Heart J 2022 · PMID 36017568For VEGF/VEGFR inhibitors, perform baseline cardiovascular risk assessment, monitor blood pressure (weekly during the first cycle, then regularly) and treat to a target <140/90 mmHg with ACE inhibitors/ARBs and dihydropyridine calcium-channel blockers; manage VEGFi-associated hypertension and proteinuria with interruption/dose modification when severe.ESCEuropean Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatmentEur Heart J Qual Care Clin Outcomes 2022 · PMID 36316010Adherence quality indicators require documented baseline cardiovascular risk assessment and structured monitoring of cardiovascular complications (including hypertension) during cancer therapy such as VEGF-pathway inhibitors.UK expert oncology/cardiology consensus panelUsing bevacizumab to treat metastatic cancer: UK consensus guidelinesBr J Hosp Med (Lond) 2010 · PMID 21135762Assess and monitor blood pressure and proteinuria during bevacizumab therapy; treat emergent hypertension to standard targets and interrupt/discontinue the drug for uncontrolled hypertension, nephrotic-range proteinuria or other severe vascular toxicity.
General onco-nephrology references
Acute Disease Quality InitiativeThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Cancer Institute NSWIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.Cancer Institute NSWAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.Cancer Institute NSWA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.